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A B S T R A C T
Osteosarcoma is a rare primary bone tumor, which mainly aﬀects children and adolescents and has a poor
prognosis, especially for patients with metastatic disease. A poor therapeutic response to the conventional
chemotherapy is observed with the development of lung metastases, highlighting the need for improving the
current regimens and the identiﬁcation of early markers of the recurrent and metastatic disease. Circulating
Tumour Cells (CTCs) play a key role in the metastatic process and could be powerful biomarkers of the pro-
gressive disease. The present study aimed to isolate CTCs by using a pre-clinical model of human osteosarcoma
and to monitor their kinetic of release and their modulation by ifosfamide. CTCs were detectable into the
bloodstream before any palpable primary tumors. Ifosfamide increased CTCs count and in contrast decreased the
number of lung tumor nodules. On established tumors, ifosfamide slowed down the tumour growth and did not
modulate CTC count that could be explained by a release of cancer cells from the primary tumour with reduced
properties for inducing lung metastases. This report highlights the biological interest of CTCs in osteosarcoma.
1. Introduction
Osteosarcoma is the most common primary malignant tumour of
bone in children and young adults. This neoplasm has its origin in
mesenchymal cells committed to the osteoblast diﬀerentiation pro-
gramme [1–3]. Malignant cells are able to destabilize the accurate os-
teoblastic/osteoclastic activity balance of bone formation and resorp-
tion that in turn facilitates the tumour cell proliferation and formation
of tumoral osteoid tissue. Conventional therapy for osteosarcoma pa-
tients combines neoadjuvant chemotherapy followed by surgical re-
moval of all detectable disease (including metastases), and post-
operative chemotherapy [1,4,5]. Current regimens of chemotherapy are
based on four drugs: i) high-dose methotrexate (HDMTX) with leu-
covorin rescue; ii) doxorubicin (adriamycin); iii) cisplatin, and iv)
ifosfamide [15]. Unfortunately, a low response rate to chemotherapy is
frequently observed leading to the development of metastases pre-
ferentially located in the lungs and ﬁnally to the patient death.
The cell dissemination process is a very complex mechanism that
involves various components of the tumour microenvironment (e.g.
blood vessels, immune cells) [7–9]. Cancer cells that have escaped from
the primary tumour and are able to invade the bloodstream to become
Circulating Tumour Cells (CTCs), that will be capable to intravasate,
survive in the circulation, migrate into the interstitial space and ﬁnally
establish the tumour growth at a new location [10–12]. Only a small
number of cells will successfully complete all the steps, thus it is im-
portant to identify and well characterize which CTCs are able to com-
plete the metastatic process [12].
Numerous studies have underlined the biological value of CTCs that
can be used as biomarkers in the follow up of epithelial malignancies
such breast and prostate cancers [13]. CTCs, which are collected, iso-
lated and characterized from a non-invasive liquid biopsy, reﬂect the
primary or/and metastatic disease for which a targeted therapy may be
given [13,14] Even if membrane vimentin or bone isoenzyme of alka-
line phosphatase appear to be expressed by a maojority of bone sar-
comas and could be used for isolating sarcoma CTCs [15–17], there is
no universal marker for the CTC detection in tumours of mesenchymal
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origin. Consequently, various methods independent of any cell markers
have been proposed and are based on size or density discrimination
[18–20]. In light of the few reports available in the literature [15–17]
and the lack of speciﬁc marker for isolating sarcoma CTCs, by using a
preclinical model of osteosarcoma, the aims of the present study were
to: i) isolate CTCs; ii) enumerate CTCs during the tumour growth and
iii) determine the eﬀect of ifosfamide treatment on CTC release.
2. Material and methods
2.1. Cell culture
HOS-MNNG human osteosarcoma cell line purchased from the
American Type Culture Collection was modiﬁed for overexpressing the
green ﬂuorescence protein (GFP) [21]. GFP-MNNG/HOS cells were
cultured in DMEM (Lonza, Belgium) supplemented with 10% FBS in a
humidiﬁed 5% CO2/air atmosphere at 37 °C.
2.2. In vivo experiments
For both experiments 6-week-old female athymic nude mice were
purchased from Elevages Janvier (France) and Harlan Laboratory (UK)
and procedures involving animal handling and care were approved by
the Animal Care and Ethics Committee of the French Ethical Committee
(CEEA.PdL.06, authorization number: 1280.01) and the Home oﬃce in
UK [PPL: 70/8967, Establishment license no.: 50/2509]. Mice were
acclimatized for at least one week prior to experimental manipulation.
Mice were anesthetized by inhalation of Isoﬂurane/air (1.5%, 1
Lmin−1) before i.m. inoculation of 1.5× 106 GFP-MNNG/HOS cells
resuspended with phosphate-buﬀered saline (PBS). Osteosarcoma cells
were injected in close proximity to the tibia, rapidly leading to tumour
growth in the soft tissue with secondary contiguous bone invasion and
development of lung metastases [22]. The tumor volumes were mon-
itored twice a week and calculated by measuring two perpendicular
diameters using calipers, according to the following formula:
V=0.523× L×(S)2, in which L and S are, respectively, the largest
and the smallest perpendicular diameters. Tumor volumes were mon-
itored until a maximum of 2500 mm3. Blood samples were collected in
EDTA tubes by intracardiac puncture in anesthetised animals and mice
were euthanized by cervical dislocation. Ifosfamide (Holoxan, Baxter)
was prepared extemporaneously, diluting with PBS and administered
intraperitoneally at doses of 15mg/kg or 30mg/kg per day on cycles of
3 consecutive days. Control mice were injected in the same conditions
with an equivalent volume of PBS. The doses used were deﬁned on the
most commonly-used dose in the literature [23–26], on the frequency
applicable in clinical practice, and on the recommendations proposed
by Reagan–Shaw et al. [27]. Lung metastastatic nodules were macro-
scopically and manually scored in each animal at the time of necropsy
as previously shown [22].
2.3. Blood processing: enrichment step of blood samples and isolation of
circulating tumour cells
Collection of CTCs from blood combined a pre-enrichment step and
an isolation phase. Pre-enrichment was carried out as follow: i) red cell
depletion carried out by incubation of blood samples with cell lysis
buﬀer for 10min at room temperature; ii) cell wash with PBS three
times consecutively; iii) leukocytes depletion using double positive se-
lection with CD45- and Tert19-microbeads (Milteny Biotec, Germany)
following the manufacturer's protocol. CTCs were the isolated either by
ﬂuorescence activated cell sorting (FACS ARIAIII, Becton Dickinson) or
by the DEPArray™ platform (Menarini, Silicon Biosystems, Italy) to
obtain pure single cells [28] (Fig. 1).
2.4. RNA extraction and gene expression analysis
Total RNA was extracted using the NucleoSpin® RNA II kit
(Macherey-Nagel Gmbh & Co. Kg, Germany). RNA was reverse tran-
scribed using the Maxima H Minus First Strand cDNA Synthesis kit
(Thermo Scientiﬁc, France) following the manufacturer's instructions.
Real-time PCR was performed with a CFX96 real-time PCR detector
system (Bio-Rad, France) with SYBR Select master Mix reagents (Life
Technologies, France). Primer sequences are detailed in supplementary
data 1.
2.5. Proliferation assay
Proliferation was determined by using a WST-1 colorimetric test
based on the cleavage of the tetrazolium salt WST-1 by mitochondrial
dehydrogenase in viable cell and according the manufacturer's re-
commendation (Takara, Japan). Two thousands cells per well were
seeded into 96 multi-well plates and after 24 h, 48 h and 72 h, cell
proliferation was assessed by optical density measurement at 470 nm
with Victor 2 1420 (Multilabel Counter, Perkin Elmer).
2.6. Migration and invasion assays
To evaluate migration ability of GFP-MNNG/HOS cells and isolated
CTCs, cells were seeded in growth media without serum on the upper
side of a Transwell chamber (Falcon) on a porous transparent poly-
ethylene terephthalate membrane (8 µm pore size). The lower chamber
of the transwell was ﬁlled with growth medium containing 10% FBS.
After 24 hours of incubation, cells on the upper side of the ﬁlters were
mechanically removed and cells migrated to the lower side were ﬁxed
(with glutaraldehyde 10%) and stained (with violet crystal 0.1%). Five
random ﬁelds were taken under light microscope and analysed for each
chamber and cells were counted with the ImageJ software (NIH, USA).
The same procedure was used for invasion assays seeding cells on the
upper side of Matrigel® (Corning, France)-coated transwells (50 ng
Matrigel/well).
2.7. Statistical analysis
Data analysis was performed using GraphPad Prism (GraphPad
Software, Inc). SEM from replicate experiments was calculated as noted
in the legends and is shown as error bars. All error bars show SEM for at
least triplicate measurement from independent experiments. The
mean± SEM was calculated for all groups and compared by non-
parametric Mann–Withney Wilconson test. SPSS statistics software
(IBM) was used for all statistical analysis. Diﬀerences were considered
signiﬁcant at the 95% conﬁdence level (p < 0.05).
3. Results
3.1. CTCs are detectable before the tumour mass in a murine model of
osteosarcoma
To validate the methods used and to avoid any bias linked to the
mode of cancer cell injection in mice, 2× 107 GFP-MNNG/HOS cells
resuspended in PBS or Matrigel® were inoculated intramuscularly in
paraosseous site. After blood collection, the presence of CTCs was
analysed by ﬂow cytometry after 24 h and 48 h post inoculation. In all
conditions used, no CTCs were observed into the blood demonstrating
that CTCs further detected were not associated to a technical artefact
such as a leak of cancer cells into the bloodstream immediately after
cell inoculation (data not shown).
We carried out a kinetic analysis of CTC release into the blood-
stream. Thirty mice previously injected with 1.5×106 GFP-MNNG/
HOS cells, were randomly divided into 3 groups and sacriﬁced at days
10, 30 and 45 respectively after cell injection (Fig. 2A). For each group,
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Fig. 1. CTC capture and characterization workﬂow. CTCs were isolate from a xenograft murine model of human osteosarcoma cells. Human GFP-MMNG/HOS
osteosarcoma cells were inoculated in close contact to the tibia of immunodeﬁcient mice. The kinetic study of CTCs detection into the bloodstream was then carried
out. A ﬁrst pre-enrichment step was performed including successively: i) a reduction of blood volume by centrifugation; ii) two lyses of erythrocytes; iii) an
immunomagnetic depletion of leukocytes and residual thrombocytes. In a second step, enriched samples were processed for isolating CTCs by ﬂow cytometry or
dielectrophoresis technology (DEPArray™). Isolated cells were enumerated, cultured and singles cells were analysed by RTqPCR.
Fig. 2. Monitoring of CTC release into the bloodstream. (A) Summary of the experimental protocole. Human GFP-MMNG/HOS osteosarcoma cells were inoculated in
paratibial site of nude mice. Tumor growth monitored (B) twice a week and the CTC dynamic (C,D) in blood were monitored at day 10, 30 and 45 after tumor cell
inoculation. CTCs were enumerated by ﬂow cytometry (C) or by DEPArray™ (D). CTCs are precociously detectable in mice before any palpable tumor mass and can be
considered an early event associated to the tumor development. D10: day 10; * p < 0.05; ** p < 0.01. n= 5/condition.
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6 samples were individually processed by ﬂow cytometry cell sorting
for CTC isolation and 4 blood samples were pooled for isolating in-
dividual CTCs with the DEPArray™. As expected, cells inoculated re-
sulted in the formation of palpable tumours growing in a time depen-
dent manner (Fig. 2B). In parallel of the tumour growth, the number of
CTCs has been increasing in a time dependent manner and CTCs were
detectable from day 10 post-cell injection, before any palpable tumour
mass and lung metastases (Fig. 2C). The early detection of CTCs was
conﬁrmed by the two methods used: ﬂow cytometry (Fig. 2C) and
DEPArray ™ (Fig. 2D).
3.2. Ifosfamide treatment results in a decrease of the primary tumour
volume and an increase of CTCs
Ifosfamide is one of the conventional drugs used in osteosarcoma.
We assessed the eﬀects of ifosfamide and more precisely the number of
CTCs, tumour volume and number of metastasis when the drug was
administered at early stages of the disease in the murine model (i.e. 10
days after tumor challenge). Fifteen mice, previously injected with GFP-
MNNG/HOS cells were divided into 3 groups: group 1, ﬁve days after
cell inoculation mice received 1 cycle of ifosfamide at a dose of 15mg/
kg (1 cycle= drug administration three consecutive days); group 2, ﬁve
days after cell inoculation mice received 1 cycle of ifosfamide at a dose
of 30mg/kg; group 3 (control group): mice received equivalent volume
of PBS (Fig. 3A). Mice were sacriﬁced at day 25 and blood samples were
collected and individually processed to isolate CTCs by cell sorting. As
shown in Fig. 3, there were no statistical signiﬁcant diﬀerences in tu-
mour volumes (Fig. 3B). However, the number of CTCs was higher in
treated groups compared to the control group (p < 0.01), and
surprisingly, the number of metastases has signiﬁcantly decreased
during the same period of time (p < 0.05) (Fig. 3C).
Then, we studied the eﬀect of the administration of multiple ifos-
famide doses. Thirty-two mice injected with GFP-MNNG/HOS cells,
randomized before treatment in two groups A and B. When the tumor
mass was palpable (D24), the mice of group A (n=8/subgroup) re-
ceived 1 cycle of ifosfamide at 30mg/Kg or PBS solution as the control
subgroup. In group B, mice were treated with 2 cycles of ifosfamide at
30mg/kg, at one week interval or PBS as the control group (Fig. 4A). As
shown in Fig. 4B, one cycle of ifosfamide reduced signiﬁcantly the
tumor growth (mean tumor volume at D33: 498.3 mm3 for treated mice
compared to 1220.5 mm3 for control; p < 0.001) but did not reduced
signiﬁcantly the number of CTCs (Fig. 4B). As expected, in treatment B,
treated mice showed a signiﬁcant decrease in tumor volumes (mean
tumor volumes at D45: 663.9 mm3 in treated mice compared to 1454.9
mm3 in control mice; p < 0.01). However two cycles ifosfamide had no
impact on CTC number compared to the vehicule group (Fig. 4C). All
together, these results revealed the diﬀerential eﬀect of ifosfamide on
the release of tumor cells according the stage of tumor development.
3.3. Molecular characterization of isolated CTCs at early stages
Isolated CTCs exhibited properties of adherence then reﬂecting in-
directly their viability. Single isolated CTCs were cultured and their
biological properties and phenotype were compared with the parental
cell line. Two cell lines (CTC1, CTC2) were then developed (Fig. 5).
Proliferation, migration, invasion assays did not show any signiﬁcant
diﬀerence between CTC1, CTC2 and the parental cell line (data not
shown). The expression of several markers related to metastatic process
Fig. 3. Opposite eﬀect of one cycle of ifosfamide on the number of lung metastases and CTCs at early stage of osteosarcoma development. (A) Summary of the
experimental protocole. Human GFP-MMNG/HOS osteosarcoma cells were inoculated in paratibial site of nude mice. Three days post-inoculation of osteosarcoma
cells, mice were treated with ifosfamide at doses of 15mg/kg or 30mg/kg i.p. per day, 3 days consecutively. Control mice were injected in the same conditions with
an equivalent volume of PBS. Tumor volume (B), number of lung metastases/mouse (lung Met.) (C) and CTCs (C) were enumerated 15 and 30 days after inoculation
of cancer cells.
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(CD99, ADAM8, ENDRA and LTK) was compared between the two
clones and the parental cell line. As shown in Fig. 5, ADAM8, LTK and
ENDRA were diﬀerentially expressed in the three cell lines and in
contrast to CD99.
4. Discussion
Osteosarcoma is the most common bone sarcoma in adolescents.
Unfortunately, a poor therapeutic response to the conventional che-
motherapy is frequently observed leading to the development of me-
tastatic foci and highlighting the need to improve the current regimens
and to identify early biomarkers of the recurrent and/or metastatic
disease. The present study analysed the biological value of CTCs into
the bloodstream in a preclinical model of osteosarcoma. CTCs were
detectable at early stage of the disease before any tumor mass. At early
stage of osteosarcoma development, one cycle of ifosfamide (15 or
30mg/Kg) had any signiﬁcant eﬀect on the primary tumor growth.
However, a high impact on the metastatic process was observed and
was characterized by a decreased number of lung metastases, and
surprisingly, by an increase in the total number of viable CTCs. At later
stage, one or two cycles of ifosfamide had a signiﬁcant beneﬁcial eﬀect
on the growth of primary tumors and no impact on the release of CTCs
into the bloodstream.
The biological relevance of CTCs has been already established in
epithelial cancers. Indeed, numerous studies demonstrated that meta-
static patients with detectable CTCs have a worse prognosis compared
to patients with undetectable CTCs [12,14]. The works focusing on the
detection and capture of CTCs in osteosarcoma have been hampered
Fig. 4. At late stage of osteosarcoma development, one cycle or two cycles of ifosfamide slow down the tumor volume without any impact on CTC release into the
bloodstream. (A) Summary of the experimental protocole. Human GFP-MMNG/HOS osteosarcoma cells were inoculated in paratibial site of nude mice. Three weeks
post-inoculation of osteosarcoma cells, mice were treated with one (B) or two cycles (C) of 30mg/kg/day i.p ifosfamide administered 3 days consecutively. Control
mice were injected in the same conditions with an equivalent volume of PBS. Tumor volume and CTCs were measured at the end-point. D0: day 0. ** p < 0.001; ***
p < 0.0001. n=8/group.
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due to the absence of speciﬁc markers expressed by mesenchymal
cancer cells [15,18–20]. However, progressively more and more cues
have strengthened the biological interest of CTCs in osteosarcoma.
Thus, Satelli et al. observed a higher number of CTCs in metastastic
patients compared to patients with localized disease. Using a method
based on isolation by size of tumor cells (ISET), Chinen et al. [29] de-
tected CTCs in sarcoma patients. More recently, Li et al. [30] conﬁrmed
the detection of CTCs in cryopreserved human peripheral blood
mononuclear cells and two studies analysing CTCs by FISH in small
cohorts of osteosarcoma patients revealed a potential positive associa-
tion between CTC count, disease progression and poor prognosis
[31,32]. The present report is the ﬁrst study investigating the regula-
tion of CTC release after chemotherapy. CTCs were detectable in blood
circulation at early stages of the disease (i.e. 10 days after cancer cell
inoculation). This ﬁnding is in agreement with previous studies in
breast [33] and prostate cancer [34]. Overall, these data suggest that
CTCs could be used as a non- invasive method to study the early bio-
logical events of osteosarcoma development and to monitor the recur-
rence of the disease in patients.
Ifosfamide belongs to the four major alkylating agents used in the
treatment of osteosarcoma including also methotrexate, cisplatin and
doxorubucin [35]. In the present report, we observed an opposite eﬀect
of ifosfamide on the CTC and lung metastasis formation at early stage of
the tumor development. Indeed, ifosfamide decreased the number of
lung nodules whereas CTC count increased on the period of time and
may be considered as a new biological tool for monitoring therapeutic
response. On established tumors, ifosfamide whatever the dose re-
gimen, had a therapeutic beneﬁt as demonstrated by a slow down of
tumor progression after drug administration. The diﬀerential eﬀects of
ifosfamide on tumor volume between early and late stages of tumor
development could be explained by the vasculature network formed in
established tumors leading to a higher bioavailability of ifosfamide
close to the tumor tissues. After inoculation, cancer cells establish cell
contact with their microenvironment and progressively proliferate and
elaborate an osteoid matrix [5,7,8]. The fragile interface between
cancer cells and their environment at early stage could explain the
signiﬁcant release of CTCs after ifosfamide treatment not observed on
later stages. CTC count was higher in large tumors than at the early
stage of the disease and was not modulated by ifosfamide revealing a
potential “equilibrium” or “saturating” state in the metastatic process in
osteosarcoma. However, CTCs detectable after ifosfamide treatment
appear unable to induce the formation of lung metastases. This increase
could be explained by a release of phenotypically altered cancer cells
from the primary tumour induced by chemotherapy and with reduced
properties for inducing lung metastases. CTC extravasation is a complex
mechanism mixing physical properties of cancer cells (e.g. lower
Fig. 5. Gene expression of CTCs compared to the parental cell line. Isolated CTCs were cultured and used for developing new cell lines. Gene expression proﬁle for
CD99, LTK, ENDRA and ADAM8 was analysed by RT-qPCR compared to Hprt1 used as house keeping gene. Relative expression of diﬀerent genes was obtained with
DDCt method.
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deformability) and biological aspects such as genetic properties and
speciﬁc addressing molecules that lead to the reciprocal recognition of
lymphatic/blood vessel walls of distant organs by CTCs. Therefore, CTC
heterogeneity and phenotypic speciﬁcities drive their extravasation into
the metastatic site and the formation of metastatic nodules [6,36].
CTCs play a key role in the metastatic process and could be powerful
biomarkers of the progressive disease or/and therapeutic response [37].
The present work analysed for the ﬁrst time the eﬀects of a conven-
tional chemotherapeutic agent in a pre-clinical model of osteosarcoma.
Overall, our study strengthens the potential interest to enumerate and
characterize CTCs in osteosarcoma. Osteosarcoma are highly prone to
induce lung metastases, which more frequently occur within 3 years
following the diagnosis and which have a major impact on the overall
survival rate. Based on the present results, CTCs appear detectable
before any tumor mass and may be considered as an early event of the
metastatic dissemination and/or may reﬂect the recurrent disease. To
assess the biological value of CTCs in osteosarcoma recurrence, murine
models could be used. The enumeration of CTCs in a murine model
based on patient-derived sarcoma xenografts or murine-tumor allograft
surgically implanted into hindlimbs, subsequently amputated followed
by an observational period of time for development of metastasis could
be an option [38–40]. The number of CTCs may reﬂect the therapeutic
response suggesting a strong clinical interest in the follow up of os-
teosarcoma patients. The lack of ifosfamide-treated CTCs to implant in
the lung should be assessed by inoculating treated CTCs in non-treated
immunodeﬁcient mice and determining their ability to establish lung
metastases. Of course, the “clinical applications” of the present work
should be taken in consideration with caution, in particular, since
ifosfamide shows a paradoxal eﬀect in patients with a therapeutic re-
sponse on established soft-tissue/para-osteal tumours but not on sub-
clinical disease. The present study should be considered as a proof-of-
conecpt for isolating CTCs in osteosarcoma in absence of universal
biomarkers. The next step of the study will be to determine the biolo-
gical and clinical value of CTC in osteosarcoma and the isolation/
enumeration/characterization of CTCs in a large series of patients (e.g.
metastastic versus non-metastatic disease; kinetic of CTC release during
chimiotherapy) will be then required.
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